Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of glu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Cardiovascular Diabetology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12933-025-02608-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850040378662584320 |
|---|---|
| author | Francisco Westermeier Enrique Z. Fisman |
| author_facet | Francisco Westermeier Enrique Z. Fisman |
| author_sort | Francisco Westermeier |
| collection | DOAJ |
| description | Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of glucagon-like peptide-1 (GLP-1) to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential. Graphical abstract |
| format | Article |
| id | doaj-art-fa92694878fc446cb61139eb51b0b8d8 |
| institution | DOAJ |
| issn | 1475-2840 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj-art-fa92694878fc446cb61139eb51b0b8d82025-08-20T02:56:06ZengBMCCardiovascular Diabetology1475-28402025-01-012411810.1186/s12933-025-02608-9Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challengesFrancisco Westermeier0Enrique Z. Fisman1Institute of Biomedical Science, Department of Health Studies, FH Joanneum University of Applied SciencesFaculty of Medicine, Tel Aviv UniversityAbstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolutionized the treatment of cardiometabolic diseases, extending their therapeutic applications far beyond glycemic control in type 2 diabetes (T2D) and obesity. This editorial synthesizes key milestones, from the discovery of glucagon-like peptide-1 (GLP-1) to recent clinical trials highlighting the pleiotropic effects of GLP-1RAs in addressing the interconnected spectrum of cardiometabolic conditions, with a focus on cardiovascular, renal, and hepatic benefits. In addition, as GLP-1RAs continue to reshape the management of cardiometabolic disease and global public health, we discuss future challenges to better elucidate their mechanisms of cardiometabolic protection and maximize their therapeutic potential. Graphical abstracthttps://doi.org/10.1186/s12933-025-02608-9Glucagon-like peptide-1 receptor agonistsGLP-1Cardiometabolic diseasesType 2 diabetesObesityChronic kidney disease |
| spellingShingle | Francisco Westermeier Enrique Z. Fisman Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges Cardiovascular Diabetology Glucagon-like peptide-1 receptor agonists GLP-1 Cardiometabolic diseases Type 2 diabetes Obesity Chronic kidney disease |
| title | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges |
| title_full | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges |
| title_fullStr | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges |
| title_full_unstemmed | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges |
| title_short | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges |
| title_sort | glucagon like peptide 1 receptor agonists glp 1ras and cardiometabolic protection historical development and future challenges |
| topic | Glucagon-like peptide-1 receptor agonists GLP-1 Cardiometabolic diseases Type 2 diabetes Obesity Chronic kidney disease |
| url | https://doi.org/10.1186/s12933-025-02608-9 |
| work_keys_str_mv | AT franciscowestermeier glucagonlikepeptide1receptoragonistsglp1rasandcardiometabolicprotectionhistoricaldevelopmentandfuturechallenges AT enriquezfisman glucagonlikepeptide1receptoragonistsglp1rasandcardiometabolicprotectionhistoricaldevelopmentandfuturechallenges |